UnitedHealth Group's stock is rated a Buy following a 59% recovery from March lows, driven by strong first-quarter results with revenue of $111.72 billion and EPS of $7.23. Management raised the full-year EPS guidance to over $18.25 and authorized a $2 billion-plus share buyback in Q2. The company's vertical integration supports its premium valuation, but potential challenges remain from Department of Justice antitrust risks and regulatory changes affecting pharmacy benefit managers. While TrumpRx poses limited threat to OptumRx, structural risks from regulatory reforms are key concerns for investors.
Piper Sandler raised its price target for UnitedHealth Group to $475, suggesting a 13.3% upside from its current price of $419.23. The company, the largest U.S. health insurer, has consistently beaten earnings estimates, with its latest EPS of $7.23 ...
The SCHD ETF has returned just under 2% in the past month, outperforming the S&P 500 ETF (SPY) by nearly 1%. Year-to-date, about 30 SCHD holdings have more than doubled the returns of SPY, which has returned 9.8%. Additionally, 31 SCHD holdings are t...
Elevance Health and UnitedHealth Group, two of the largest U.S. health insurers, are set to report their second-quarter earnings this week. Investors and analysts are watching closely to see if these companies have maintained control over rising medi...
